Medisan(SZ:002900) Zheng Quan Zhi Xing·2025-06-12 12:41Core Viewpoint - The announcement details the share reduction plans of key executives at Harbin Sanlian Pharmaceutical Co., Ltd., including specific timelines and the number of shares to be sold [1][2][3]. Group 1: Shareholders' Information - The shareholders planning to reduce their holdings include Liang Yanfei (Vice President and Secretary of the Board), Zhu Zihong (Director), and Zhao Zhicheng (CFO) [1]. - As of the announcement date, the shareholding situation of the shareholders is as follows: Liang Yanfei holds 808,800 shares (0.2557% of total shares), Zhu Zihong holds 100,000 shares (0.0316%), and Zhao Zhicheng also holds 100,000 shares (0.0316%) [1]. Group 2: Reduction Plan Details - Liang Yanfei plans to reduce his holdings by up to 202,200 shares (25% of his holdings), which represents 0.0639% of the company's total shares [3]. - Zhu Zihong and Zhao Zhicheng each plan to reduce their holdings by 25,000 shares (25% of their holdings), which is 0.0079% of the company's total shares [3]. - The reduction period is set from July 7, 2025, to October 6, 2025, with a stipulation that no shares will be sold during the window period [1][3]. Group 3: Compliance and Commitments - Liang Yanfei has adhered to the commitments made in the company's IPO prospectus regarding share transfers, which include restrictions on the number of shares that can be sold within specific time frames [2][4]. - The reduction plan is consistent with previously disclosed commitments by the shareholders, ensuring compliance with relevant regulations [4].